BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Lorcaserin regulatory update

FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 9-5 that the benefit-risk profile of Arena's lorcaserin did not support approval to treat obesity. While panel members agreed that lorcaserin had met the efficacy criteria outlined in draft guidance for obesity...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >